Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).
Location: United States, Michigan, Ann Arbor
Employees: 11-50
Total raised: $92M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | Turenne Ca... | turennecap... |
| - | Adams Stre... | adamsstree... |
| - | Altitude L... | altitudels... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.08.2018 | - | $30M | - |
| 05.01.2016 | Series B | $62M | - |
Mentions in press and media 12
| Date | Title | Description |
| 27.03.2019 | Roundup: QL Demo Day, Millendo Therapeutics, Strata Oncology, More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints —Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletid... |
| 09.08.2018 | OvaScienceSM and Millendo Therapeutics Merge; New Company Raises $30M | OvaScienceSM (Nasdaq:OVAS) and Millendo Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, have entered into a definitive agreement under to me... |
| 12.01.2018 | How female founders are faring in the Midwest | Women remain underrepresented in tech, even as the industry tries to address jaw-dropping statistics about their absence in tech’s upper echelon. Less than 3 percent of female founders raised venture capital in 2017, even though in the firs... |
| 12.01.2018 | How female founders are faring in the Midwest | Women remain underrepresented in tech, even as the industry tries to address jaw-dropping statistics about their absence in tech’s upper echelon. Less than 3 percent of female founders raised venture capital in 2017, even though in the firs... |
| 12.01.2018 | How female founders are faring in the Midwest | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Women remain underrepresented in tech, even as th... |
| 20.12.2017 | After axing a top drug, Millendo bags a PhII replacement with biotech buyout | Millendo Therapeutics has acquired a small French biotech named Alizé Pharma SAS ̶ and its Phase II obesity-related drug ̶ in a deal that helps fill out Millendo’s previously thinning pipeline in orphan endocrine diseas... |
| 20.05.2017 | Why I love the Detroit startup scene | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! People often ask me, “Why did you move from San F... |
| 20.05.2017 | Why I love the Detroit startup scene | People often ask me, “Why did you move from San Francisco to, uh, Detroit?” The answer is easy. In 10 years, San Francisco will be as good as it is today, but Detroit will be a roaring city once again, defining a new technology hub at the i... |
| 13.09.2016 | Millendo Launches Phase 2b Study of PCOS Drug After Year of Growth | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Millendo Therapeutics, the Ann Arbor, MI-based biotech company developing drugs to treat endocrine diseases, last month began Phase 2b clinical trials for MLE4901, a non-hormo... |
| 05.01.2016 | Daily funding roundup - January 5, 2016 | PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me... |
Show more